New York Life Investment Management LLC Arcus Biosciences, Inc. Transaction History

New York Life Investment Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	BUY	$14.83 - $20.18 $34,642 - $47,140	2,336 Added 12.24%	21,416 $404,000
Q4 2023 Feb 05, 2024	SELL	$13.43 - $19.63 $5,909 - $8,637	-440 Reduced 2.25%	19,080 $364,000
Q3 2023 Nov 07, 2023	SELL	$17.62 - $23.54 $54,181 - $72,385	-3,075 Reduced 13.61%	19,520 $350,000
Q2 2023 Aug 04, 2023	SELL	$16.97 - $22.03 $60,718 - $78,823	-3,578 Reduced 13.67%	22,595 $458,000
Q1 2023 May 08, 2023	BUY	$15.96 - $23.15 $417,721 - $605,904	26,173 New	26,173 $477,000

196

51.6M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $906M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of New York Life Investment Management LLC, based on Form 13F filings with the SEC.

Stay updated on New York Life Investment Management LLC with notifications on news.